1naresh2naresh<pre>Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

    [cb09cc7e-4607-4c5c-a445-a0bd2c9af51d] => Array
        (
            [runtime-id] => cb09cc7e-4607-4c5c-a445-a0bd2c9af51d
            [type] => toll-free-key
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [3f22122b-7813-466e-8691-5d5c58391193] => Array
                        (
                            [runtime-id] => 3f22122b-7813-466e-8691-5d5c58391193
                            [type] => toll-free-key
                        )

                )

            [credentials] => Array
                (
                    [method] => toll-free-key
                    [value] => tf_ipsecsha;22bcbafb6fa2d4b4341912f3313abba4c83af657
                )

        )

)
1naresh2naresh<pre>Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => FreeToRead
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

    [f219c908-9096-44c8-afb5-8c13f2345604] => Array
        (
            [runtime-id] => f219c908-9096-44c8-afb5-8c13f2345604
            [type] => toll-free-key
            [service-id] => ajnr-ac.highwire.org
            [access-type] => FreeToRead
            [privilege] => Array
                (
                    [df48471c-e7c0-489c-a261-a01665fe8c0d] => Array
                        (
                            [runtime-id] => df48471c-e7c0-489c-a261-a01665fe8c0d
                            [type] => toll-free-key
                        )

                )

            [credentials] => Array
                (
                    [method] => toll-free-key
                    [value] => tf_ipsecsha;22bcbafb6fa2d4b4341912f3313abba4c83af657
                )

        )

)
RT Journal Article
SR Electronic
T1 Panitumumab (Vectibix)
JF American Journal of Neuroradiology
JO Am. J. Neuroradiol.
FD American Society of Neuroradiology
SP 1002
OP 1003
DO 10.3174/ajnr.A2601
VO 32
IS 6
A1 Gemmete, J.J.
A1 Mukherji, S.K.
YR 2011
UL http://www.ajnr.org/content/32/6/1002.abstract
AB Panitumumab (Vectibix), is a human monoclonal antibody EGFR antagonist indicated as a single agent for the treatment of metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine, oxaliplatin, and irinotecan chemotherapy regimens. This article will present the mechanism of action as well as the clinical role for this monoclonal antibody. c-erbB-1EGFR geneEGFRepidermal growth factor receptorFDAUS Food and Drug AdministrationHERhuman epidermal growth factor receptorKRASKristen rat sarcoma viral oncogene homolog